Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03793179
Title Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Pembrolizumab + Pemetrexed Disodium

Pembrolizumab

Carboplatin + Pemetrexed Disodium

Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST